IngredientsPalmitic acid (hexadecanoic acid in IUPAC nomenclature) is a fatty acid with a 16-carbon chain. It is the most common saturated fatty acid found in animals, plants, and microorganisms. Its chemical formula is CH3(CH2)14COOH, and its C:D ratio (the total number of carbon atoms to the number of carbon-carbon double bonds) is 16:0.
The compound has a molecular weight of 256.42408 g/mol, a molecular formula of C16H32O2, a CAS registry number of 57-10-3, and a PubChem CID of 985. It is a white solid that melts at 63.1°C. It belongs to the group of saturated fatty acids, with no double bond and a shorthand notation of 16:0. It is also a member of the group called long-chain fatty acids (LCFA), from 14 to 18 carbon atoms.
Palmitates are the salts and esters of palmitic acid. The palmitate anion is the observed form of palmitic acid at physiologic pH (7.4). It exists in nature primarily as a triglyceride and other esters.
Palmitic acid is a major component of palm oil from the fruit of Elaeis guineensis (oil palms), making up to 44% of total fats. Meats, cheeses, butter, and other dairy products also contain palmitic acid, amounting to 50–60% of total fats. Major sources of C16:0 are palm oil, palm kernel oil, coconut oil, and milk fat.
As the name suggests, PA is a major component of palm oil (44% of total fats), but significant amounts of PA can also be found in meat and dairy products (50–60% of total fats), as well as cocoa butter (26%) and olive oil (8–20%). Furthermore, PA is present in breast milk with 20–30% of total fats.
In humans, palmitic acid has been seen to make up 21% to 30% of human depository fat. It can be found in blood, cerebrospinal fluid, feces, saliva, sweat, and urine, and also in tissues including adipose tissue, the bladder, skin, fibroblasts, kidney, placenta, platelet, prostate, and skeletal muscle.
On average, a 70-kg man is made up of 3.5 kg of PA.
The average dietary intake of PA is around 20–30 g/d, representing about 8–10% of energy, and can be found in different vegetable and animal fat sources, with levels of 20–30% in animal lipids and 10–45% in vegetable oils.
Palmitic acid (16 carbon atoms), from the French word palmitique, was first purified by Chevreul M.E. in his research on butter and tallow (also known as beef fat), but was surely characterized by Frémy E. in 1840 in saponified palm oil, from which its name derives. The knowledge of palmitic acid dates to 1840, when French chemist Edmont Frémy made it by saponifying palm oil, a process that is still used to manufacture the compound.
An early mention of palmitic acid in the chemical literature came in an 1879 report by Thomas Carnelley and W. Carleton Williams at Owens College (Manchester, UK; eventually the University of Manchester), who measured the boiling point of its potassium salt. In the ensuing years of the 19th century, palmitic acid and its derivatives appeared in dozens of articles about its sources, properties, and uses.
Palmitic acid, as such, was not historically isolated and consumed as a named compound — it existed and was consumed as an integral component of ancient dietary fats and oils. Unlike many botanical supplements, there is no recorded tradition of palmitic acid being intentionally prepared as a medicinal or nutritional agent prior to its chemical characterization in the 19th century. Its history is therefore primarily the history of the foods in which it was the dominant fatty acid.
Palm oil derived from Elaeis guineensis has been used as a food and medicine in West and Central Africa for thousands of years. Archaeological and ethnobotanical evidence documents palm oil as a staple cooking fat and food preservative across West African cultures, and it was traded extensively along ancient African trade routes before European contact. The oil was also introduced to the Americas and Asia through historical trade and colonial commerce. In these traditional contexts, the fatty acids within palm oil — predominantly palmitic acid — constituted a major part of the dietary fat intake of populations in these regions, though without any explicit attribution to palmitic acid specifically.
In commercial production, palmitic acid is derived from vegetable oils and animal fats through a process called hydrolysis, in which triglycerides are broken down by water into various fatty acids and glycerol. Both palmitic acid and its sodium salt form are widely used in a variety of applications, as they are inexpensive, and are widely used in foods as food additives. It is also used in cosmetic formulations and the making of soaps, waterproofing materials, and organic synthesis.
Because it is inexpensive and adds texture and "mouthfeel" to processed foods, palmitic acid and its sodium salt find wide use in foodstuffs. Sodium palmitate is permitted as a natural additive in organic products.
PA is the most common saturated fatty acid, accounting for 20–30% of total fatty acids in the human body, and can be provided in the diet or synthesized endogenously via de novo lipogenesis (DNL). Palmitic acid is the first fatty acid produced during fatty acid synthesis in humans and the fatty acid from which longer fatty acids can be produced.
In the de novo synthesis pathway, glucose and glutamine are enzymatically catalyzed to produce citrate, which is cleaved to acetyl-CoA and oxaloacetate. Acetyl-CoA is carboxylated to malonyl-CoA, which is condensed by the repeated actions of fatty acid synthase (FASN) to produce PA.
PA tissue content seems to be controlled around a well-defined concentration, and changes in its intake do not influence significantly its tissue concentration because the exogenous source is counterbalanced by PA endogenous biosynthesis. Particular physiopathological conditions and nutritional factors may strongly induce DNL, resulting in increased tissue content of PA and disrupted homeostatic control of its tissue concentration.
Plasma palmitic acid is derived from dietary fat and also endogenously from de novo lipogenesis and lipolysis. DNL is affected by excess energy intake resulting in overweight and obesity, and the macronutrient profile of the diet. A low-fat diet (higher carbohydrate and/or protein) promotes palmitic acid synthesis in adipocytes and the liver. A high-fat diet is another source of palmitic acid that is taken up by adipose tissue, liver, heart, and skeletal muscle via lipolytic mechanisms.
Fatty acid esters are prolific producers of adenosine triphosphate (ATP), the main energy source in living cells. According to one account, one palmitate molecule generates 129 molecules of ATP. Palmitate undergoes beta-oxidation in the mitochondria, producing acetyl-CoA, NADH, and FADH2, which feed into the citric acid cycle and oxidative phosphorylation.
Palmitic acid is itself the bioactive entity, functioning at multiple levels of cellular biology. Its mechanisms of action span membrane structure, post-translational protein modification, pulmonary surfactant composition, lipid signaling, and inflammatory pathways.
PA represents 20–30% of total fatty acids in membrane phospholipids and adipose triacylglycerols. The tight homeostatic control of PA tissue concentration is likely related to its fundamental physiological role to guarantee membrane physical properties, but also to enable protein palmitoylation, palmitoylethanolamide (PEA) biosynthesis, and in the lung an efficient surfactant activity. In order to maintain membrane phospholipid balance, an optimal intake of PA in a certain ratio with unsaturated fatty acids — especially PUFAs of both n-6 and n-3 families — may be crucial.
Palmitoylation, a reversible post-translational lipid modification, involves the covalent attachment of palmitic acid (a 16-carbon saturated fatty acid) to cysteine residues on target proteins via a thioester bond. This modification is catalyzed by palmitoyl acyltransferases (PATs), with the DHHC family (defined by its conserved Asp-His-His-Cys catalytic motif) being the most studied group. The approximately 23 human DHHC enzymes are integral membrane proteins typically localized to the Golgi apparatus, endoplasmic reticulum, and plasma membrane, exhibiting distinct tissue distribution.
S-palmitoylation is a covalent post-translational modification of proteins which consists in the attachment of PA to specific cysteines via a thioester bond. S-palmitoylated proteins vary in number from ~50 in yeast to several hundred in mammals. S-palmitoylation raises the hydrophobicity of cytoplasmic proteins in a manner similar to other lipid alterations such as myristoylation and prenylation, thereby increasing their affinity for cytosolic membrane surfaces.
Palmitoylation increases the hydrophobicity of proteins and plays an important role in regulating protein stability, conformation, transport, membrane binding, and interactions with lipids and other proteins. Unlike other lipid modifications, S-palmitoylation achieves modification through unstable thioester bonds, a property that makes it the only reversible modification of protein lipidation.
Overall, palmitoylation is implicated in key cellular functions including signal transduction, differentiation, transcriptional regulation, and metabolism. Dysregulation of palmitoylation has been implicated in a plethora of diseases, such as metabolic syndrome, cancers, neurological disorders, and infections.
Dipalmitoylphosphatidylcholine (DPPC) is a phospholipid consisting of two C16 palmitic acid groups attached to a phosphatidylcholine head-group. It is the main constituent of pulmonary surfactants, which reduces the work of breathing and prevents alveolar collapse during breathing. Lung surfactant disaturated phosphatidylcholine (PC) is highly dependent on the supply of palmitate as a source of fatty acid.
Palmitic acid serves as the direct fatty acid precursor for palmitoylethanolamide (PEA), an endogenous lipid mediator with established anti-inflammatory and neuroprotective properties. The tight homeostatic control of PA tissue concentration is likely related to its fundamental physiological role to guarantee membrane physical properties but also to enable protein palmitoylation, palmitoylethanolamide (PEA) biosynthesis, and in the lung an efficient surfactant activity.
De novo ceramide biosynthesis requires the coordinate action of serine palmitoyl transferase and ceramide synthase to generate ceramide. This process begins with the condensation of serine and palmitoyl-CoA to form 3-ketosphinganine, which is reduced to the sphingoid base sphinganine and acylated by ceramide synthase to generate dihydroceramide. This compound is oxidized to ceramide by introduction of a trans-4,5 double bond.
Palmitic acid may affect cardiovascular disease risk via mechanisms beyond increasing LDL-C, notably through synthesis of ceramides and possibly through branched fatty acid esters of hydroxy fatty acids (FAHFAs) from palmitic acid. Ceramides are positively associated with incident CVD, whereas the role of FAHFAs is uncertain.
Saturated fatty acids such as palmitic acid promote inflammation and insulin resistance in peripheral tissues, contrasting with the protective action of polyunsaturated fatty acids such as docosahexaenoic acid. Palmitic acid effects have been in part attributed to its potential action through Toll-like receptor 4 (TLR4). Palmitic acid up-regulates TLR4 as well as pro-inflammatory cytokines IL-6 and TNFα.
PA can induce atherosclerosis by altering blood cholesterol levels, particularly through elevating LDL-C levels. PA inhibits the expression of LDL receptors and accelerates the secretion of very low-density lipoprotein (VLDL) from the liver.
The relationships between intake and tissue levels of saturated fatty acids and cardiovascular disease risk have been extensively studied over the past six decades. Individual SFAs differ in their metabolic effects. Palmitic acid (C16:0) is the most abundant SFA in the U.S. diet, representing about 55% of dietary SFAs, and comprises about 20–30% of all fatty acids in membrane phospholipids and triglycerides.
Clinical and observational evidence indicates that palmitic acid from both exogenous and endogenous sources is adversely associated with CVD risk, as well as total mortality. It is well established that dietary palmitic acid increases low-density lipoprotein cholesterol (LDL-C); however, palmitic acid also likely increases CVD risk via other mechanisms.
It is well accepted in the medical community that palmitic acid from dietary sources raises low-density lipoprotein (LDL) and total cholesterol. The World Health Organization has stated there is convincing evidence that palmitic acid increases cardiovascular disease risk.
In clinical cohort studies of 1,040 patients with coronary heart disease, high levels of PA were associated with risk of major adverse cardiovascular events (MACE) and death.
A cross-sectional analysis of circulating fatty acid levels and metabolic risk factors in 172 healthy, normal-weight (BMI: 22.6 ± 3.5) adults showed that total SFA concentrations were significantly positively correlated with waist circumference, TG, LDL-C, total cholesterol, systolic blood pressure, and diastolic blood pressure. Interestingly, circulating palmitic acid was not significantly associated with any metabolic risk factors in this healthy population. However, studies in at-risk populations tend to report opposite results.
A prospective metabolomics crossover trial explored dietary fatty acid effects on cardiometabolic risk markers. Comprehensive metabolomic profiling tools were applied to biological specimens collected from 18 healthy adults enrolled in a crossover trial that compared a 3-week high–palmitic acid diet with a low–palmitic acid and high–oleic acid diet. Epidemiologic evidence has suggested that diets with a high ratio of palmitic acid to oleic acid increase risk of cardiovascular disease.
When compared with palmitic acid, stearic acid lowers LDL-cholesterol — a well-known risk factor for coronary heart disease — but its effects on other cardiometabolic risk markers have been studied less extensively. The positional distribution of these two fatty acids within the triacylglycerol molecule may affect their metabolic effects. Interesterification of palmitic acid- or stearic acid-rich fats does not seem to affect fasting serum lipids and lipoproteins. On the other hand, stearic acid decreases the LDL- and HDL-cholesterol concentrations when compared with palmitic acid.
The evidence linking dietary palmitic acid intake to raised LDL-C and cardiovascular disease risk is strong, supported by decades of clinical trials, prospective cohort studies, and endorsed by the WHO. The mechanistic pathways (LDL receptor suppression, ceramide synthesis, endothelial dysfunction) are well-characterized but much of the mechanistic detail derives from in vitro and animal studies. The precise contribution of dietary palmitic acid versus endogenously synthesized palmitic acid to CVD risk remains an area of active investigation.
Elevated levels of free fatty acids are associated with insulin resistance, dyslipidemia, increased low-density lipoprotein, and inflammatory cytokine levels, all of which play crucial roles in cardiometabolic diseases such as obesity, atherosclerosis, and type 2 diabetes. Free fatty acids like palmitic acid are elevated in obesity and diabetes and dysregulate monocyte and macrophage functions, contributing to enhanced inflammation in these cardiometabolic diseases.
Growing evidence suggests a strong link between PA diet and various diseases, including obesity, type 2 diabetes mellitus, cardiovascular diseases, and cancers. PA induces mitochondrial ROS generation and desensitizes the insulin signaling pathway via JNK (through TLR4) and impairs IRS-2 phosphorylation in hepatic cell lines; conversely, treatment with anti-oxidants attenuates the insulin resistance and reduces ROS generation.
In the brain, palmitic acid and resistin trigger neuroinflammation and insulin resistance. Using the human SH-SY5Y neuroblastoma cell line, researchers showed that palmitic acid treatment impaired insulin-dependent Akt and Erk phosphorylation, whereas DHA (docosahexaenoic acid) preserved insulin action.
Since PUFAs, particularly n-3 highly unsaturated PUFAs, suppress lipogenic gene expression, their reduction in intake rather than excess of dietary SFA may promote endogenous PA production via DNL. Thereby, the increase in tissue PA and its deleterious consequences from dysregulated DNL can be mistakenly attributed to dietary intake of PA.
Evidence for palmitic acid's role in promoting insulin resistance and inflammatory signaling is substantial at the cellular and mechanistic level, but predominantly from in vitro studies and animal models. Human interventional data are more limited; the contribution of dietary versus endogenous palmitic acid to metabolic disease risk requires careful interpretation.
Epigenetic mechanisms regulating enhancer functions play key roles in inflammatory gene expression; palmitic acid treatment was found to alter the epigenetic landscape of enhancers and super-enhancers in human monocytes.
Saturated fatty acids, particularly PA, promote cardiovascular pathogenesis through pro-inflammatory, dyslipidemic, and endothelial dysfunction pathways.
In a study conducted at the Minneapolis Community Atherosclerosis Risk Center, 3,870 white men and women aged 45–64 years were assessed for plasma cholesterol esters and phospholipid fatty acids, revealing a significant positive correlation between plasma SFAs (particularly PA) and ischemic stroke.
The pro-inflammatory actions of palmitic acid are supported by cell culture studies and some human observational data. Much mechanistic evidence on TLR4 activation and NF-κB signaling derives from in vitro work, with limited prospective human trial data specifically focused on isolated palmitic acid interventions.
The relationship between palmitic acid and cancer is complex, with evidence pointing in opposing directions depending on context, concentration, cancer type, and study model.
Palmitic acid intake is associated with an increased cancer risk, including prostate cancer.
Dietary palmitic acid acts as a potent inducer of YAP signaling in metastasis in breast and ovarian cancers, achieved by increasing the expression of the palmitoyltransferase ZDHHC15. These findings uncover a ZDHHC15-YAP feedback loop as a previously unrecognized mechanism underlying PA-promoted tumor metastasis.
The excess fatty acid synthesis that results from the coordinated activation of lipogenic enzymes in many types of cancer leads to the accumulation of palmitate, which needs to be further processed by the cells due to the toxic effects of its accumulation.
Modern pharmacological studies have demonstrated that PA exhibits anti-inflammatory, antioxidant, and immune-enhancing effects. In recent years, PA has emerged as a promising anti-tumor agent with demonstrated efficacy against various malignancies including gastric cancer, liver cancer, cervical cancer, breast cancer, and colorectal cancer. Its anti-tumor effects encompass inducing apoptosis in tumor cells, inhibiting tumor cell proliferation, suppressing metastasis and invasion, enhancing sensitivity to chemotherapy, and improving immune function.
A mechanistic study indicated that palmitic acid inhibited the key molecules of the PI3K/Akt pathway to block prostate cancer proliferation and metastasis. Prostate cancer is one of the most frequent causes of cancer death in men worldwide, and novel drugs for prostate cancer therapies are still being developed.
We cannot exclude possible membrane protein modifications by palmitoylation and myristoylation leading to alterations of localization and function of key proteins for tumor suppression. In vitro and in vivo studies suggest that specific fatty acids could promote cell invasiveness or metastasis. However, only confusing results have been obtained on the action of selected fatty acids in cell signaling transduction pathways, in particular in cell proliferation and apoptosis.
The cancer-related evidence for palmitic acid is predominantly preclinical (cell line and animal model data). Human epidemiological associations between palmitic acid intake and cancer risk exist for prostate cancer (observational data), but causal, controlled human trial evidence is lacking. The dual pro- and anti-tumorigenic findings underscore the complexity of this area and the need for further research.
Dipalmitoylphosphatidylcholine (DPPC) is a phospholipid consisting of two C16 palmitic acid groups attached to a phosphatidylcholine head-group. It is the main constituent of pulmonary surfactants, which reduces the work of breathing and prevents alveolar collapse during breathing.
Lung surfactant disaturated phosphatidylcholine is highly dependent on the supply of palmitate as a source of fatty acid. The importance of de novo fatty acid synthesis in the regulation of disaturated PC production during late prenatal lung development has been specifically investigated.
It is estimated that approximately 45% of surfactant DPPC is formed via de novo synthesis, while the other 55–75% is generated by remodeling.
The role of palmitic acid as the obligate building block of DPPC — the dominant lipid in pulmonary surfactant — is well established in biochemical, developmental, and clinical lung physiology research. This is a fundamental, not supplemental, physiological role.
Recent evidence suggests that both exogenous dietary intake and endogenous biosynthesis of fatty acids can serve as sources of substrates for protein palmitoylation. This modification plays a pivotal role in modulating membrane localization and protein stability, and its dysregulation is closely associated with various neurodegenerative diseases, including Parkinson's disease.
Palmitic acid (16:0; PAM) is a saturated fatty acid with 16 carbon atoms. Recent studies have demonstrated that PAM plays a critical role in neurodegenerative diseases by modulating transcription factor activity.
The neurodegenerative disease associations of dysregulated palmitoylation are an emerging area. Evidence is currently preclinical (cell culture, animal models, genetic association studies). Human clinical interventional data are absent. This area warrants caution against overclaiming.
A 2021 review indicated that replacing dietary palmitic acid and other saturated fatty acids with unsaturated fatty acids, such as oleic acid, could reduce several biomarkers of cardiovascular and metabolic diseases.
The 2020–2025 Dietary Guidelines for Americans recommend that SFAs provide less than 10% of total energy, which is based on strong evidence demonstrating reductions in LDL-C when SFAs are replaced with unsaturated fatty acids. Furthermore, replacing SFAs with PUFAs reduces risk of coronary artery disease.
Palmitic acid is not typically marketed or consumed as a standalone dietary supplement in the manner of vitamins or herbal extracts. It is consumed primarily as a component of natural foods and fats.
The average dietary intake of PA is around 20–30 g/d, representing about 8–10% of energy.
Both palmitic acid and its sodium salt form are widely used in a variety of applications, as they are inexpensive, and are widely used in foods as food additives. Palmitic and stearic acid are the main fatty acids in E 470a and E 470b food additives and were already considered of no safety concern in the re-evaluation of the food additive E 570. The fatty acid moieties of E 470a and E 470b contributed maximally 5% to the overall intake of saturated fatty acids from all dietary sources. The EFSA Panel concluded that there was no need for a numerical ADI and that the food additives sodium, potassium, calcium, and magnesium salts of fatty acids were of no safety concern at the reported uses and use levels.
In the human crossover trial comparing palmitic acid and oleic acid dietary interventions, 18 healthy adults were enrolled in a 3-week high–palmitic acid or high–oleic acid dietary comparison. The specific gram-per-day dose of isolated palmitic acid was embedded in the total dietary fat composition of the trial diet rather than administered as a supplement.
In animal studies of cardiovascular endpoints, in ApoE−/− mice, 10 mg/kg palmitic acid treatment induced blood pressure elevation, cardiac contractile dysfunction, endothelial dysfunction, and atherosclerotic plaque formation. This animal dose cannot be directly extrapolated to human dietary dosing.
The palmitate ester can be used to synthesize paliperidone palmitate (9-hydroxyrisperidone), an atypical antipsychotic class of medication used to treat schizophrenia. This pharmaceutical use involves the palmitate ester as a prolonged-release vehicle, not as a therapeutic molecule in its own right.
Palmitic acid is a part of the intravenous ultrasonic contrast agent Levovist, which is used during ultrasounds to detect certain diseases.
As regards the specific fatty acids (E 570) that were the subject of EFSA opinion, the proposal was as follows: intake of saturated fatty acid (caprylic-, capric-, lauric-, myristic-, palmitic-, and stearic acid) as low as possible; no DRV was set for cis-monounsaturated fatty acids (oleic acid).
Palmitic and stearic acid were already considered of no safety concern in the re-evaluation of the food additive E 570.
It is well accepted in the medical community that palmitic acid from dietary sources raises low-density lipoprotein (LDL) and total cholesterol. The World Health Organization has stated there is convincing evidence that palmitic acid increases cardiovascular disease risk.
A systematic review concluded that although interesterification of palmitic and stearic acid-rich fats did not affect serum lipids overall, substitution of palmitic acid with stearic acid lowered LDL cholesterol.
Some saturated fatty acids, including oleic acid, can counteract the negative impact of PA on cellular health, suggesting a complex interaction between different dietary fats and cellular outcomes. Therefore, the challenge is to prevent the lipid peroxidation of dietary unsaturated fatty acids through the utilization of natural antioxidants.
A low-fat diet (higher carbohydrate and/or protein) promotes palmitic acid synthesis in adipocytes and the liver. Since PUFAs, particularly n-3 highly unsaturated PUFAs, suppress lipogenic gene expression, their reduction in intake rather than excess of dietary SFA may promote endogenous PA production via DNL. This means both very high-carbohydrate low-fat diets and high saturated-fat diets can elevate circulating palmitate, albeit through different routes.
Contribution by dietary means is physiologically relevant, and an optimal intake of PA in a certain ratio with unsaturated fatty acids, especially PUFAs of both n-6 and n-3 families, may be crucial. Fatty acid metabolism appears to be directed to reach an optimal PUFA/SAFA ratio in tissues for maintaining fatty acid membrane phospholipid balance.
Overweight/obesity and accompanying insulin resistance increase non-esterified fatty acid (NEFA) production. Experimental and clinical studies suggest that elevated levels of PA from both exogenous and endogenous sources are adversely associated with cardiometabolic disease risk and mortality.
The positional distribution of palmitic and stearic acids within the triacylglycerol molecule may affect their metabolic effects. The position of palmitic acid within dietary triglycerides (sn-1, sn-2, or sn-3) influences absorption and downstream metabolic outcomes, though this remains an area of active research.
Palmitic acid is the predominant fatty acid in human breast milk, and DPPC (dipalmitoylphosphatidylcholine) is essential for neonatal lung development. DPPC is the main constituent of pulmonary surfactants, which reduces the work of breathing and prevents alveolar collapse. Exogenous surfactant preparations containing DPPC are used clinically in premature neonates with respiratory distress syndrome.
Health conditions that Palmitic acid may help support.
Palmitic acid promotes endothelial dysfunction and atherosclerosis through multiple mechanisms including palmitoylation of PKM2, induction of oxidative stress, and triggering of TLR4-mediated vascular inflammation. A clinical cohort of 1,040 CHD patients showed high serum palmitic acid significantly increased risk of MACE and death. Epidemiological studies across diverse populations link high dietary palmitic acid with elevated atherosclerosis risk.
Palmitic acid is the most abundant saturated fatty acid in human breast milk, comprising 26–28% of total milk fatty acids, uniquely positioned at the sn-2 carbon of triglycerides. This sn-2 configuration (beta-palmitate) enhances fat and calcium absorption in infants, improves stool consistency, and positively influences the infant gut microbiome. It is a defining structural feature of human milk fat.
Multiple RCTs and meta-analyses confirm that dietary palmitic acid raises LDL-cholesterol. Replacing it isoenergetically with unsaturated fatty acids reduces LDL-C by approximately 0.36 mmol/L across 18 RCTs, with similar reductions in total cholesterol and apolipoprotein B. This LDL-raising effect is the primary basis for dietary recommendations to limit saturated fat.
Palmitic acid is a direct ligand for Toll-like receptor 4 (TLR4) on human immune cells, triggering NF-κB activation and pro-inflammatory cytokine release including IL-1β, IL-6, and TNF-α. This has been demonstrated in human dendritic cells, macrophages, and myotubes. Elevated circulating palmitic acid is positively associated with systemic inflammatory markers in clinical cohort data.
Palmitic acid is a natural component of the skin's lipid barrier, alongside ceramides and cholesterol. Applied topically, it functions as an emollient that forms a protective film, prevents transepidermal water loss, and supports the stratum corneum barrier against dryness, irritants, and allergens. It is widely used in dermatological formulations for dry skin at concentrations of 5–15%.
Palmitic acid is an essential component of infant body fat, membrane lipids, and signaling molecules during early development. At birth, term infants are 13–15% body fat with 45–50% consisting of palmitic acid, much derived from fetal endogenous synthesis. Human milk delivers approximately 10% of infant dietary energy as palmitic acid in the sn-2 position, supporting fat and calcium absorption critical for growth.
Clinical and observational evidence consistently links elevated dietary and circulating palmitic acid with increased cardiovascular risk, including higher LDL-cholesterol and major adverse cardiac events. In a cohort of 1,040 coronary heart disease patients, high serum palmitic acid was associated with significantly lower survival and higher rates of MACE. The mechanism involves endothelial injury via protein palmitoylation and upregulation of inflammatory pathways.
Palmitic acid is established as a direct inducer of insulin resistance across multiple human-relevant tissue types including hepatocytes, skeletal muscle myotubes, and neuronal cells. It impairs insulin signaling via mitochondrial ROS, ceramide synthesis, and TLR4 activation. The relationship is one of harm to insulin sensitivity rather than support.
Palmitic acid is the structural building block of dipalmitoylphosphatidylcholine (DPPC), the principal component of pulmonary surfactant that reduces alveolar surface tension and prevents lung collapse during breathing. DPPC consists of two palmitic acid C16 chains, and its fully saturated structure is essential for effective surface tension reduction during exhalation. Palmitic acid also enhances surfactant surface activity and confers resistance to inhibition by blood proteins.
Chronic elevation of palmitic acid—from dietary sources or de novo lipogenesis—is mechanistically linked to the core features of metabolic syndrome: insulin resistance, dyslipidemia, inflammation, and hepatic steatosis. Clinical and epidemiological data associate high palmitic acid exposure with each individual component of the syndrome.
Palmitic acid is both a major constituent of circulating triglycerides and a driver of de novo lipogenesis-derived triglyceride production. Clinical studies show that diets enriched in palmitic acid can alter postprandial triglyceride-rich lipoprotein profiles, increasing proatherogenic remnant particles. Palmitic acid's role in hepatic triglyceride accumulation underpins its central involvement in NAFLD pathogenesis.
Body systems that Palmitic acid may help support.
Go back